TriangleCladribine, Cytarabine, and… (NCT04050280)
Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO) trial for Acute Myeloid Leukemia, Adult (NCT04050280). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with acute myeloid leukemia after intensive-treatment failure or first relapse, with CD33 expression on at least twenty percent of cells. Acute promyelocytic leukemia is excluded.
The idea: gemtuzumab ozogamicin delivers a DNA-damaging drug through CD33. It joins cladribine, cytarabine, and G-CSF during inpatient induction. Responders may proceed to donor transplantation or consolidation; those remaining in remission after consolidation may receive gemtuzumab maintenance. Researchers assess remission and safety.
This phase 2 study plans 39 patients. Vu Duong leads at the University of Maryland, Baltimore, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.